查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751295

美国马再生医学市场规模、份额和趋势分析报告：按产品、应用、最终用途、州和细分市场预测，2025 年至 2030 年

U.S. Equine Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Stem Cells, Platelet-Rich Plasma (PRP)), By Application, By End Use, By State, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

美国马再生医学市场的成长与趋势

根据 Grand View Research, Inc. 的最新报告，美国马再生医学市场规模预计到 2030 年将达到 8,044 万美元，预测期内复合年增长率为 8.31%。

推动市场成长的关键因素是运动和表演马匹中肌肉骨骼损伤的盛行率不断增加、再生医学日益融入马匹保险和护理模式、马匹再生医学的进步、宠物的人性化以及马主消费者信心的不断增强。

肌肉骨骼损伤，包括肌腱炎、韧带断裂、关节损伤和骨关节炎，在美国运动马和表演马中越来越常见。障碍赛、马场马术、绕桶赛和耐力赛等马术运动的兴起将马匹推向了它们的身体极限，增加了软组织和关节损伤以及其他相关併发症的风险。传统治疗方法（如非类固醇抗发炎药和手术）通常会导致癒合不完全和较高的再次受伤率。再生疗法，如富血小板血浆、干细胞疗法和 Prostride（一种自体蛋白溶液），因其能够在细胞层面促进组织修復而越来越受欢迎。这些方法可以加快恢復速度，完全恢復马的运动能力，并降低復发风险。

例如，间质干细胞(MSC) 疗法正越来越多地被用于治疗悬韧带撕脱伤，这是赛马和跳马运动员常见的损伤。研究表明，MSC 可以减轻炎症，改善肌腱纤维排列，从而实现更彻底的癒合。此类治疗现已成为诊所和就诊医院的标准做法，预示着由于损伤氾滥，市场将迎来强劲增长。

此外，兽医再生医学领域的科学创新正在推动市场发展。过去十年，分离、扩增和递送干细胞及生物药品的技术变得更有效率、更经济且可扩展。对细胞生物学、组织工程和生物材料的理解正在改善治疗效果并扩大应用范围。

根据 Equine Network LLC 在 2025 年 2 月发布的数据，注射金疗法 (GOLDIC) 已成为治疗方法马匹骨关节炎 (OA) 和其他肌肉骨骼疾病的一种有前景的方法。透过将马血与亲水性金粒子一起孵育，可以获得富含细胞激素和生长因子的血清，这些血清可以减少发炎并促进再生。在最近的一项研究中，GOLDIC 显着改善了马匹的跛行、储存积液和肿胀症状，其中许多马匹在 3-6 个月后症状消失。 GOLDIC 是一种创新治疗方法，与传统治疗方法相比，它可以长期改善症状，并可能获得寻求更永续解决方案的兽医和马主的支持。凭藉其在减少发炎和促进组织再生方面的已证实的有效性，GOLDIC 可能会刺激马匹领域采用更先进的骨科生物疗法。这可能会增加对再生疗法的需求，吸引更多投资，并影响马匹各种肌肉骨骼和软组织损伤的类似治疗方法的发展。

美国马再生医学市场报告重点

  • 从产品来看，预计干细胞领域将在2024年占据最大的市场占有率，达到61.75%。这归功于干细胞能够促进组织再生，改善癒合质量，并减少关节、肌腱和韧带损伤造成的疤痕形成。勃林格殷格翰收购全球干细胞技术公司（Global Stem Cell Technology）等策略性投资，正将干细胞定位为未来马匹医疗保健的基石，进一步加速创新。
  • 根据应用情况，预计预测期内创伤和伤口护理领域将以最快的复合年增长率（8.65%）增长。这得益于受伤率的上升以及人们对马匹健康意识的不断提高。干细胞、富血小板血浆、自体蛋白溶液、IRAP（免疫修復再生疗法）和羊膜衍生产品等再生疗法的创新显着改善了伤口癒合，减少了疤痕形成。 Zaracil 先进的伤口护理配方等产品已展现出以科学为支撑的再生解决方案的潜力。如此快速的技术进步使创伤护理将成为未来几年市场成长的关键驱动力。
  • 从最终用途来看，兽医研究实验室预计将成长最快，预测期内复合年增长率为8.75%，这得益于其在技术创新和临床检验中的关键作用。他们的研究为再生疗法的安全性和有效性提供了关键证据，并鼓励更广泛的临床应用。透过推动组织修復和疾病预防领域的突破，这些实验室正在塑造马匹医疗保健的未来。
  • 到2024年，德克萨斯州将以16.61%的市占率占据市场占有率主导地位。由于非侵入性治疗需求的不断增长、干细胞和富血小板血浆疗法的创新以及马匹数量的庞大，预计该州的市场将快速增长。生技公司与兽医诊所之间的策略联盟、收购和合作，例如Ardent Equine与Pegasus Orthobiologics的合作以及Vetirus Pharmaceuticals对Enso Discoveries的收购，正在进一步加强创新和治疗开发，使佛罗里达州成为该领域的领导者。

目录

第一章调查方法与范围

第二章执行摘要

3. 北美马再生医学市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 补贴市场前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
    • 市场机会分析
    • 市场问题分析
    • 产业分析—波特五力分析
    • PESTEL分析
  • 2024年美国主要州马匹数量估计
  • 法律规范
  • 美国马业人口统计数据
    • 品种类型
    • 活动类型（例如运动）
    • 马术产业事实与数据
  • 按产品进行价格分析
  • 产品平臺分析/临床试验分析
  • 保险覆盖范围分析

第四章美国马再生医学市场：产品、估计与趋势分析

  • 细分仪表板
  • 美国马再生医学市场：产品差异分析，百万美元，2024 年对比 2030 年
    • 干细胞
    • 富血小板血浆（platelet-richplasma）
    • 其他的

第五章美国马再生医学市场：应用预测与趋势分析

  • 细分仪表板
  • 美国马再生医学市场：应用变化分析，百万美元，2024 年和 2030 年
    • 整形外科
    • 创伤/创伤护理
    • 其他的

第六章。美国马再生医学市场最终用途、估计和趋势分析

  • 细分仪表板
  • 美国马再生医学市场：最终用途差异分析，百万美元，2024 年对比 2030 年
    • 兽医院/诊所
    • 兽医研究所
    • 其他的

第七章美国马再生医学市场：国家估计与趋势分析

  • 2024 年及 2030 年各州市场占有率分析
  • 州立市场仪表板
  • 州市场概况
  • 2018-2030年市场规模、预测与趋势分析
  • 美国
    • 德克萨斯
    • 加州
    • 佛罗里达
    • 俄亥俄州
    • 奥克拉荷马
    • 肯塔基州
    • 密苏里州
    • 宾州
    • 科罗拉多
    • 其他州

第八章 竞争态势

  • 企业参与者的分类
  • 企业市场分析/热图分析
  • 公司简介
    • Boehringer Ingelheim International GmbH
    • Zoetis
    • Dechra Pharmaceuticals Plc
    • Equine Amnio Solutions
    • VetStem, Inc.
    • Hilltop Bio
    • Equi-Stem LLC
    • Ardent Equine
    • Pronoia BIoTech
    • Medrego
    • AniCell BioTech
    • PetVivo Holdings, Inc.（Spyrng）
    • Arthrex Inc.
    • Contura Vet
    • Nucleus ProVets LLC
    • Enso Discoveries（Vetirus Pharmaceuticals）
    • Gallant Therapeutics
    • Astaria Global
    • Interpath Global（4CYTE）
    • American Regent, Inc.
  • 战略地图
    • 合併与收购
    • 伙伴关係和合作
    • 扩张
    • 产品发布
    • 其他的
  • 其他主要参与企业名单
Product Code: GVR-4-68040-586-8

U.S. Equine Regenerative Medicine Market Growth & Trends:

The U.S. equine regenerative medicine market size is expected to reach USD 80.44 million by 2030, registering a CAGR of 8.31% over the forecast period, according to a new report by Grand View Research, Inc. The primary factors driving the market growth are the increasing prevalence of musculoskeletal injuries in sport & performance horses, the growing integration of regenerative medicine into equine insurance & practice models, advancements in equine regenerative medicine, and the growing pet humanization & equine owner willingness to spend.

Musculoskeletal injuries such as tendonitis, ligament tears, joint damage, and osteoarthritis are increasingly common among sport and performance horses in the U.S. These injuries significantly reduce performance ability, lead to prolonged recovery, and may end careers prematurely. The rise in competitive equestrian events like show jumping, dressage, barrel racing, and endurance racing pushes horses to their physical limits, increasing the risk of soft tissue, joint injuries and other related complications. Traditional therapies (like NSAIDs, surgery) often result in incomplete healing and high rates of re-injury. Regenerative therapies, including platelet-rich plasma (PRP), stem cell therapy, and Pro-Stride (autologous protein solution), are gaining traction due to their ability to enhance tissue repair at the cellular level. These approaches promote faster recovery and can restore the horse to full athletic performance, reducing the risk of recurrence.

An example is the increased adoption of mesenchymal stem cell (MSC) therapy to treat suspensory ligament desmitis, a common injury in racehorses and jumpers. Studies show MSCs can reduce inflammation and improve tendon fiber alignment, leading to more complete healing. Clinics and referral hospitals now offer such treatments as standard, indicating strong market growth based on injury prevalence.

Furthermore, scientific innovations in veterinary regenerative medicine propel the market forward. Over the past decade, techniques for isolating, expanding, and delivering stem cells or biologic agents have become more efficient, cost-effective, and scalable. Understanding cell biology, tissue engineering, and biomaterials has improved treatment outcomes and broadened applications.

As per data published in February 2025 by Equine Network LLC, injectable gold therapy (GOLDIC) is emerging as a promising treatment for equine osteoarthritis (OA) and other musculoskeletal conditions. By incubating the horse's blood with hydrophilic gold particles, the therapy produces a serum rich in cytokines and growth factors that help reduce inflammation and promote regeneration. In a recent study, GOLDIC significantly improved symptoms of lameness, joint effusion, and swelling in horses, with many becoming asymptomatic after three to six months. As an innovative therapy that offers long-term relief compared to traditional treatments, it could gain traction among veterinarians and horse owners looking for more sustainable solutions. With proven efficacy in reducing inflammation and enhancing tissue regeneration, GOLDIC might encourage the adoption of more advanced orthobiologic treatments in the equine sector. This could increase demand for regenerative therapies, attracting more investment and potentially influencing the development of similar treatments for various musculoskeletal and soft tissue injuries in horses.

U.S. Equine Regenerative Medicine Market Report Highlights:

  • Based on product, the stem cells segment held the largest market share of 61.75% in 2024. This can be attributed to its ability to promote proper tissue regeneration, improve healing quality, and reduce scar formation in joint, tendon, and ligament injuries. Strategic investments, such as Boehringer's acquisition of Global Stem Cell Technology, further accelerate innovation, positioning stem cells as a cornerstone of future equine healthcare.
  • Based on application, the trauma/ wound care segment is expected to grow at the fastest CAGR of 8.65% over the forecast period. This can be attributed to the rising incidence of injuries and increasing awareness of equine health. Innovations in regenerative therapies-such as stem cells, PRP, autologous protein solutions, IRAP, and amniotic-derived products-significantly improve healing and reduce wound scarring. Products like Zarasyl's advanced wound care formulations showcase the potential of science-backed regenerative solutions. This rapid technological advancement positions trauma care as a key driver of future market growth
  • By end use, the veterinary research institutes segment is expected to grow at the fastest CAGR of 8.75% during the forecast period. This can be owed to their pivotal role in innovation and clinical validation. Their research provides critical evidence supporting the safety and efficacy of regenerative treatments, encouraging wider clinical adoption. By driving breakthroughs in tissue repair and disease prevention, these institutes are shaping the future of equine healthcare.
  • The state of Texas dominated the market in 2024 with a share of 16.61%. It is expected to grow rapidly, driven by rising demand for non-invasive treatments and innovations in stem cell and PRP therapies, and the presence of a large horse population. Strategic partnerships, acquisitions, and collaborations between biotech companies and veterinary institutions, like Ardent Equine's partnership with Pegasus Orthobiologics and Vetirus Pharmaceuticals' acquisition of Enso Discoveries, further enhance innovation and therapy development, positioning Florida as a leader in the sector.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
  • 1.6. Market Formulation & Visualization
  • 1.7. Data Validation & Publishing
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
    • 1.8.2. Volume Price Analysis
    • 1.8.3. Global Market: CAGR Calculation
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Companion Animal Medicine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Musculoskeletal Injuries in Sport and Performance Horses
      • 3.2.1.2. Increasing Integration of Regenerative Medicine into Equine Insurance and Practice Models
      • 3.2.1.3. Advancements in Equine Regenerative Medicine
      • 3.2.1.4. Growing Pet Humanization and Equine Owner Willingness to Spend
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Regenerative Therapies
      • 3.2.2.2. Regulatory Ambiguity and Lack of Standardization
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
    • 3.2.5. Industry Analysis - Porter's
      • 3.2.5.1. Bargaining power of the suppliers
      • 3.2.5.2. Bargaining power of the buyers
      • 3.2.5.3. Threats of substitution
      • 3.2.5.4. Threats from new entrants
      • 3.2.5.5. Competitive rivalry
    • 3.2.6. PESTEL Analysis
      • 3.2.6.1. Political landscape
      • 3.2.6.2. Economic and Social landscape
      • 3.2.6.3. Technological landscape
  • 3.3. Estimated Equine Population in U.S. Key States, 2024
  • 3.4. Regulatory Framework
  • 3.5. Equine Industry Demographics in the U.S.
    • 3.5.1. Type of Breeds
    • 3.5.2. Type of Activity (Sports & Others)
    • 3.5.3. Equestrian Industry Facts & Figures
  • 3.6. Pricing Analysis, by Product
  • 3.7. Product Pipeline Analysis/Clinical Trials Analysis
  • 3.8. Insurance Coverage Analysis

Chapter 4. U.S. Equine Regenerative Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Equine Regenerative Medicine Market: By Product Movement Analysis, USD Million, 2024 & 2030
    • 4.2.1. Stem Cells
      • 4.2.1.1. Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Platelet-Rich Plasma (PRP)
      • 4.2.2.1. Platelet-Rich Plasma (PRP) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3. Others
      • 4.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Equine Regenerative Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Equine Regenerative Medicine Market: By Application Movement Analysis, USD Million, 2024 & 2030
    • 5.2.1. Orthopedics
      • 5.2.1.1. Orthopedics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Trauma/ Wound Care
      • 5.2.2.1. Trauma/ Wound Care Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Others
      • 5.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Equine Regenerative Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Equine Regenerative Medicine Market: By End Use Movement Analysis, USD Million, 2024 & 2030
    • 6.2.1. Veterinary Hospitals/Clinics
      • 6.2.1.1. Veterinary Hospitals/Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Veterinary Research Institutes
      • 6.2.2.1. Veterinary Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Equine Regenerative Medicine Market: State Estimates & Trend Analysis

  • 7.1. State Market Share Analysis, 2024 & 2030
  • 7.2. State Market Dashboard
  • 7.3. State Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Texas
      • 7.5.2.1. Texas market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. California
      • 7.5.3.1. California market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Florida
      • 7.5.4.1. Florida market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Ohio
      • 7.5.5.1. Ohio market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Oklahoma
      • 7.5.6.1. Oklahoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Kentucky
      • 7.5.7.1. Kentucky market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Missouri
      • 7.5.8.1. Missouri market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Pennsylvania
      • 7.5.9.1. Pennsylvania market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.10. Colorado
      • 7.5.10.1. Colorado market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.11. Other States
      • 7.5.11.1. Other States market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Company Profile
    • 8.3.1. Boehringer Ingelheim International GmbH
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Zoetis
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Dechra Pharmaceuticals Plc
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Equine Amnio Solutions
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. VetStem, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Hilltop Bio
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Equi-Stem LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Ardent Equine
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Pronoia Biotech
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Medrego
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AniCell BioTech
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. PetVivo Holdings, Inc. (Spyrng)
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Arthrex Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Contura Vet
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. Nucleus ProVets LLC
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Enso Discoveries (Vetirus Pharmaceuticals)
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives
    • 8.3.17. Gallant Therapeutics
      • 8.3.17.1. Company overview
      • 8.3.17.2. Financial performance
      • 8.3.17.3. Product benchmarking
      • 8.3.17.4. Strategic initiatives
    • 8.3.18. Astaria Global
      • 8.3.18.1. Company overview
      • 8.3.18.2. Financial performance
      • 8.3.18.3. Product benchmarking
      • 8.3.18.4. Strategic initiatives
    • 8.3.19. Interpath Global (4CYTE)
      • 8.3.19.1. Company overview
      • 8.3.19.2. Financial performance
      • 8.3.19.3. Product benchmarking
      • 8.3.19.4. Strategic initiatives
    • 8.3.20. American Regent, Inc.
      • 8.3.20.1. Company overview
      • 8.3.20.2. Financial performance
      • 8.3.20.3. Product benchmarking
      • 8.3.20.4. Strategic initiatives
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Expansion
    • 8.4.4. Product launch
    • 8.4.5. Others
  • 8.5. List of other Key players

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Estimated Equine Population in U.S. key states, 2024.
  • Table 4. Pricing analysis by key products
  • Table 5. U.S. Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 6. U.S. Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 7. U.S. Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8. U.S. Equine Regenerative Medicine Market, by State, 2018 - 2030 (USD Million)
  • Table 9. Texas Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 10. Texas Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 11. Texas Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12. California Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 13. California Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 14. California Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15. Florida Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 16. Florida Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 17. Florida Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18. Ohio Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 19. Ohio Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 20. Ohio Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21. Oklahoma Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 22. Oklahoma Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 23. Oklahoma Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Kentucky Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 25. Kentucky Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 26. Kentucky Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 27. Missouri Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 28. Missouri Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 29. Missouri Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Pennsylvania Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 31. Pennsylvania Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 32. Pennsylvania Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 33. Colorado Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 34. Colorado Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 35. Colorado Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 36. Other States Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 37. Other States Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 38. Other States Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39. Company Overview
  • Table 40. Product Benchmarking
  • Table 41. Financial Performance
  • Table 42. Strategic Initiatives

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Equine Regenerative Medicine Market, Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 State Marketplace: Key Takeaways
  • Fig. 14 U.S. Equine Regenerative Medicine Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Equine Regenerative Medicine Market, for Stem Cells, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Equine Regenerative Medicine Market, for Platelet-Rich Plasma (PRP), 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Equine Regenerative Medicine Market, for Others , 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Equine Regenerative Medicine Market, for Application, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Equine Regenerative Medicine Market, for Orthopedics, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Equine Regenerative Medicine Market, for Trauma/Wound Care, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Equine Regenerative Medicine Market, for End Use, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Equine Regenerative Medicine Market, for Veterinary Hospitals/Clinics, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Equine Regenerative Medicine Market, for Veterinary Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 State Outlook, 2024 & 2030
  • Fig. 27 Texas Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 28 California Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 29 Florida Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 30 Ohio Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 31 Oklahoma Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 32 Kentucky Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 33 Missouri Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 34 Pennsylvania Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 35 Colorado Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 36 Other States Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 37 Market participant categorization
  • Fig. 38 Heat map analysis
  • Fig. 39 Strategic Framework